Both EMN and MK have been infrequently described as drug-related toxicities in cancer patients treated with BRAF (v-Raf murine sarcoma viral oncogene homolog B)-targeted therapies but have not been documented to occur simultaneously at the onset of anti-BRAF medication. Here, BRAF is linked to cancer.